arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

AEON Biopharma, Inc.

AEON

$0.28 0.00 (-1.28%) at close

19 Visible periods

19 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, AEON Biopharma, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $11.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC 28.0%

FCF / Share $-0.06

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-11.79M

↑ +68.2% —

FCF / Share Free cash flow per share

$-0.06

↑ +96.7% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of 0.44x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2022 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2022 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2021 10-K ↗	Q3 FY2022 Sep 30, 2021 10-Q ↗	Q2 FY2022 Jun 30, 2021 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2020 10-K ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗
EPS Growth YoY (%)	N/M	N/M	96.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	-25.7% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-95.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	-2334.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	N/M	N/M	26.5% Excellent Excellent Year-over-year change in net income	N/M	N/M	-74.4% Weak ↓ Weak Declining Year-over-year change in net income	40.9% Excellent ↓ Excellent Declining Year-over-year change in net income	5817.4% Excellent ↑ Excellent Improving Year-over-year change in net income	-569.1% Weak ↓ Weak Declining Year-over-year change in net income	3176.7% Excellent Excellent Year-over-year change in net income	N/M	-56.1% Weak Weak Year-over-year change in net income	N/M	—	—	—	—	—	—
FCF Growth YoY (%)	96.7% Excellent → Excellent Stable Year-over-year change in free cash flow	—	95.9% Excellent → Excellent Stable Year-over-year change in free cash flow	98.7% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	88.0% Excellent Excellent Year-over-year change in free cash flow	—	31.1% Excellent Excellent Year-over-year change in free cash flow	—	-189.6% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2022 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2022 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2021 10-K ↗	Q3 FY2022 Sep 30, 2021 10-Q ↗	Q2 FY2022 Jun 30, 2021 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2020 10-K ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗
Effective Tax Rate (%) (%)	—	—	—	—	—	—	—	—	—	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.9% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—
FCF / Net Income (x)	0.22x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.13x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.31x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.87x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.30x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.48x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.05x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.07x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-1.70x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.44x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.63x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.05x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.07x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	-0.09x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2022 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2022 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2021 10-K ↗	Q3 FY2022 Sep 30, 2021 10-Q ↗	Q2 FY2022 Jun 30, 2021 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2020 10-K ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗
Return on Invested Capital (%)	28.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	—	9.9% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	21.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	3.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	6.5% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—	3.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	4.1% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—	—	0.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-68.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-99.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.2% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-3.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-73.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	-174.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-0.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-0.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-0.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	70.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+369%)	—	22.8% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+52%)	41.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+179%)	-80.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-635%)	—	—	—	—	-2.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-119%)	—	-22.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-249%)	—	-1.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-110%)	—	—	-33.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-324%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2022 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2022 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2021 10-K ↗	Q3 FY2022 Sep 30, 2021 10-Q ↗	Q2 FY2022 Jun 30, 2021 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2020 10-K ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗
Net Debt (USD)	$-6.24M	$-3.01M	$-5.93M	$-8.44M	$-10.45M	$-13.00K	—	—	—	$-9.75M	—	$-7.76K	—	—	—	—	$-497.41K	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2022 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2022 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2021 10-K ↗	Q3 FY2022 Sep 30, 2021 10-Q ↗	Q2 FY2022 Jun 30, 2021 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2020 10-K ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗
Basic EPS, GAAP (USD)	$-0.29	$-3.72	$-0.39	$-0.60	$2.28	$3.21	$-11.24	$304.00	$-227.87	$4.32	$-5.76	—	$-9.36	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.06	—	$-0.22	$-0.19	$-1.99	—	$-5.38	$-15.03	$-16.61	—	$-7.81	—	$-5.73	—	—	—	—	—	—
Book Value per Share (USD)	$-0.66	—	$-1.71	$-1.37	$-1.07	—	—	—	—	$-149.10	—	—	—	—	—	—	—	—	—
Tangible Book Value per Share (USD)	$-0.66	—	$-1.71	$-1.37	$-1.07	—	—	—	—	$-149.10	—	—	—	—	—	—	—	—	—
Basic Weighted Avg Shares (shares)	40.61M	—	11.63M	11.09M	3.98M	—	549,175	539,840	517,915	—	1.93M	—	1.93M	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2022 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2022 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2021 10-K ↗	Q3 FY2022 Sep 30, 2021 10-Q ↗	Q2 FY2022 Jun 30, 2021 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2020 10-K ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗
Working Capital (USD)	$-44.00K	$-3.50M	$-816.00K	$1.13M	$3.68M	$-12.56M	—	—	—	$-72.74M	—	$-717.48K	—	$639.00	—	—	$639.00	—	$21.41K
Total Equity (USD)	$-16.75M	—	$-19.87M	$-15.85M	$-11.32M	—	—	—	—	$-287.50M	—	$-12.37M	—	$-16.93M	—	—	$-18.84M	$21.41K	$21.41K

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2022 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2022 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2021 10-K ↗	Q3 FY2022 Sep 30, 2021 10-Q ↗	Q2 FY2022 Jun 30, 2021 10-Q ↗	Q1 FY2022 Dec 31, 2021 10-Q ↗	Q4 FY2021 Dec 31, 2020 10-K ↗	Q1 FY2021 Dec 31, 2020 10-Q ↗
Depreciation Expense (USD)	$19.00K	$20.00K	$19.00K	$20.00K	$19.00K	$23.00K	$25.00K	$24.00K	$25.00K	$14.00K	$21.00K	—	$25.00K	—	—	—	—	—	—
Net Income, GAAP (USD)	$-11.79M	$-37.14M	$-4.54M	$-6.64M	$9.10M	$2.08M	$-6.17M	$164.11M	$-118.02M	$8.12M	$-10.44M	$2.77M	$-17.64M	$247.87K	$6.32M	$6.32M	$6.32M	—	—
Operating Cash Flow (USD)	$-2.64M	$-4.71M	$-2.60M	$-2.09M	$-7.91M	$-621.00K	$-2.96M	$-8.12M	$-8.60M	$-13.84M	$-15.06M	—	$-11.06M	$-162.63K	$-325.31K	$-452.32K	$-554.52K	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 19 quarters

AEON Biopharma, Inc.

Analytical Summary

19-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare AEON with peers